| Mutated neuron navigator 3 as a candidate gene for a rare neurodevelopmental disorder. | Mutated neuron navigator 3 as a candidate gene for a rare neurodevelopmental disorder.
Umair M, Alharbi M, Aloyouni E, Al Abdulrahman A, Aldrees M, Al Tuwaijri A, Bilal M, Alfadhel M., Free PMC Article | 08/7/2024 |
| Variants of NAV3, a neuronal morphogenesis protein, cause intellectual disability, developmental delay, and microcephaly. | Variants of NAV3, a neuronal morphogenesis protein, cause intellectual disability, developmental delay, and microcephaly.
Ghaffar A, Akhter T, Strømme P, Misceo D, Khan A, Frengen E, Umair M, Isidor B, Cogné B, Khan AA, Bruel AL, Sorlin A, Kuentz P, Chiaverini C, Innes AM, Zech M, Baláž M, Havrankova P, Jech R, Ahmed ZM, Riazuddin S, Riazuddin S., Free PMC Article | 08/2/2024 |
| Tumour Suppressor Neuron Navigator 3 and Matrix Metalloproteinase 14 are Co-expressed in Most Melanomas but Downregulated in Thick Tumours. | Tumour Suppressor Neuron Navigator 3 and Matrix Metalloproteinase 14 are Co-expressed in Most Melanomas but Downregulated in Thick Tumours.
Bugaeva O, Maliniemi P, Prestvik WS, Leivo E, Kluger N, Salava A, Virtanen S, Jäntti K, Saksela O, Lehti K, Kujala P, Krohn K, Ranki A., Free PMC Article | 03/10/2023 |
| Together, our findings suggest an important role for miR-21 in the progression of HCC, which negatively regulated Navigator-3 in the migration of HCC. | MiR-21 promoted proliferation and migration in hepatocellular carcinoma through negative regulation of Navigator-3.
Wang Z, Yang H, Ren L. | 04/30/2016 |
| The authers propose that NAV3 inhibits breast cancer progression by regulating microtubule dynamics, biasing directionally persistent rather than random migration, and inhibiting locomotion of initiated cells. | Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression.
Cohen-Dvashi H, Ben-Chetrit N, Russell R, Carvalho S, Lauriola M, Nisani S, Mancini M, Nataraj N, Kedmi M, Roth L, Köstler W, Zeisel A, Yitzhaky A, Zylberg J, Tarcic G, Eilam R, Wigelman Y, Will R, Lavi S, Porat Z, Wiemann S, Ricardo S, Schmitt F, Caldas C, Yarden Y., Free PMC Article | 11/7/2015 |
| Data indicate that neuron navigator 3 (NAV3) may be a potential new prognostic biomarker and a potential therapeutic target. | Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis.
Carlsson E, Krohn K, Ovaska K, Lindberg P, Häyry V, Maliniemi P, Lintulahti A, Korja M, Kivisaari R, Hussein S, Sarna S, Niiranen K, Hautaniemi S, Haapasalo H, Ranki A. | 05/25/2013 |
| NAV3 has a role in linking tissue inflammation to cancer development in the colon. | Potential role of a navigator gene NAV3 in colorectal cancer.
Carlsson E, Ranki A, Sipilä L, Karenko L, Abdel-Rahman WM, Ovaska K, Siggberg L, Aapola U, Ässämäki R, Häyry V, Niiranen K, Helle M, Knuutila S, Hautaniemi S, Peltomäki P, Krohn K., Free PMC Article | 03/31/2012 |
| characterized copy number changes of NAV3 in 24 basal cell cancers, eight squamous cell cancers and eight non-malignant inflammatory skin lesions | NAV3 copy number changes and target genes in basal and squamous cell cancers.
Maliniemi P, Carlsson E, Kaukola A, Ovaska K, Niiranen K, Saksela O, Jeskanen L, Hautaniemi S, Ranki A. | 03/10/2012 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators., Free PMC Article | 09/15/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD, ASCOT investigators, NORDIL investigators, BRIGHT Consortium., Free PMC Article | 09/15/2010 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| NAV3 gene would not be frequently deleted in cutaneous type leukemia/lymphoma including those with mycosis fungoides-like manifestations | Cutaneous-type adult T-cell leukemia/lymphoma does not primarily show deletion of NAV3 gene.
Kawai K, Uchida Y, Yonekura K, Virtanen S, Tähtinen M, Krohn K, Ranki A, Kanekura T. | 02/1/2010 |
| An imbalanced fluorescence in situ hybridization pattern between NAV3 and pericentromeric control probes was seen in three patients in accordance with CGH array data. No NAV3 specific breakpoint or partial deletion was detected. | Primary cutaneous T-cell lymphomas do not show specific NAV3 gene deletion or translocation.
Marty M, Prochazkova M, Laharanne E, Chevret E, Longy M, Jouary T, Vergier B, Beylot-Barry M, Merlio JP. | 01/21/2010 |
| Allelic NAV3 aberrations (LOH or deletion by FISH were identified in 44% of the subcutaneous panniculitis-like T-cell lymphoma samples. | Clinicopathological characterization and genomic aberrations in subcutaneous panniculitis-like T-cell lymphoma.
Hahtola S, Burghart E, Jeskanen L, Karenko L, Abdel-Rahman WM, Polzer B, Kajanti M, Peltomäki P, Pettersson T, Klein CA, Ranki A. | 01/21/2010 |